Aclidinium Bromide Gains Reluctant Advisory Committee Recommendation
This article was originally published in The Pink Sheet Daily
Pulmonary-Allergy Drugs Advisory Committee members say post-marketing study is necessary, and Forest has already made a preliminary proposal.
You may also be interested in...
Only about one-third of biosimilars received a first-cycle approval from US FDA after product quality discussions during the mid-assessment-cycle meeting, according to an interim report on the biosimilar application review program.
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.